Amphastar Pharmaceuticals, Inc.

Healthcare · Drug Manufacturers - Specialty & Generic

26.30$ +5.2% vs. previous close Closing price · As of: Sep 24, 2026

Statements

Income Statement

Amphastar Pharmaceuticals, Inc. (AMPH) by the numbers: income statement, balance sheet and cash flow, by year or by quarter. In the most recent period (Q2 26), "Revenue" came in at 184 million USD. Tick rows to compare them in a chart.

Income Statement Balance Sheet Cash Flow Ratios

Annual Quarterly

Amounts Change % Common size % Per share

Last 12 Full history

Download as CSV

All figures in millions of USD.

Tick rows to compare them in a chart (up to 4)

Income Statement AMPH
Line item	Q3 16	Q4 16	Q1 17	Q2 17	Q3 17	Q4 17	Q1 18	Q2 18	Q3 18	Q4 18	Q1 19	Q2 19	Q3 19	Q4 19	Q1 20	Q2 20	Q3 20	Q4 20	Q1 21	Q2 21	Q3 21	Q4 21	Q1 22	Q2 22	Q3 22	Q4 22	Q1 23	Q2 23	Q3 23	Q4 23	Q1 24	Q2 24	Q3 24	Q4 24	Q1 25	Q2 25	Q3 25	Q4 25	Q1 26	Q2 26	LTM
Revenue	64	64	57	65	58	60	58	71	76	90	80	79	80	83	85	86	83	96	103	102	112	121	120	123	120	135	140	146	181	178	172	182	189	187	171	174	192	183	171	184	730
Cost of Revenue	37	44	34	38	37	40	41	45	46	55	49	47	45	50	48	53	47	59	58	54	61	65	65	60	62	64	66	73	72	82	85	87	87	100	85	88	93	97	101	90	382
Gross Profit	28	20	23	27	21	21	17	26	29	35	31	32	35	33	37	33	37	37	45	47	51	56	56	63	59	71	74	73	108	96	87	95	102	87	85	86	99	86	70	93	348
Research & Development	9.7	12	11	11	10	11	14	15	11	17	15	16	19	20	15	16	18	18	15	18	11	17	16	23	19	17	20	17	17	20	14	18	21	18	20	20	22	23	27	22	95
Selling, General & Administrative	11	11	11	12	12	9.2	11	12	13	14	16	12	11	11	11	16	12	12	15	15	11	11	12	10.0	12	11	13	12	13	13	16	13	15	13	16	14	39	16	18	18	92
Total Operating Expenses	22	24	24	25	23	22	27	29	27	33	34	31	33	34	29	36	33	34	35	37	26	32	34	39	35	33	40	36	36	42	39	40	45	42	48	44	73	50	57	54	234
Operating Income	5.8	-4.5	1.4	2.2	-2.8	-1.7	-9.9	-2.9	2.6	1.5	-3.2	1.0	2.4	-0.2	7.5	-2.9	3.5	2.9	10	11	25	24	22	25	23	38	33	37	73	54	48	55	57	45	37	42	25	36	14	40	114
Interest Expense	0.3	0.1	0.2	0.2	0.3	0.1	0.0	0.1	0.1	0.0	0.0	0.0	0.0	0.0	0.1	0.0	0.2	0.1	0.1	0.1	0.5	0.2	0.4	0.4	0.6	0.5	0.4	3.6	14	9.5	8.6	8.6	6.7	6.4	6.3	6.3	6.3	6.6	6.6	6.7	26
Pre-Tax Income	6.0	-4.6	1.5	3.2	-2.0	-1.1	-9.0	-4.1	2.6	0.6	-3.6	61	1.6	1.2	5.8	-1.5	7.1	-6.7	5.1	14	38	27	28	23	22	41	33	33	63	41	47	50	48	44	31	39	22	32	10	39	102
Income Tax Expense	2.1	-1.9	0.6	1.2	-2.2	-2.5	-1.8	-1.3	1.0	-1.1	-1.5	14	0.6	0.4	2.3	-0.1	2.3	-1.0	1.2	5.6	6.7	7.2	4.1	5.6	6.6	7.3	6.8	6.4	14	4.7	4.1	12	7.3	6.0	5.6	8.3	4.2	7.5	3.6	8.2	23
Net Income	3.9	-2.7	0.9	2.0	0.2	1.5	-7.2	-2.8	2.4	1.9	0.9	48	1.3	-1.0	3.9	-0.2	3.9	-6.3	5.0	7.8	30	20	24	17	16	34	26	26	49	36	43	38	40	38	25	31	17	24	6.4	30	79
EBITDA	9.5	-0.7	2.6	7.3	2.1	3.0	-5.1	0.1	6.8	5.9	0.9	6.7	7.7	6.9	12	4.4	14	0.1	12	21	45	34	36	30	30	49	41	43	91	65	70	73	69	65	52	62	42	55	33	45	175

LTM = last twelve months (sum of the four most recent quarters).

Showing the most recent 40 periods — older statements are on file for this stock.

Data as of: September 24, 2026 · Source: fundamental data & SEC filings (annual and quarterly reports, 10-K/10-Q)

Note: pure fact-based analysis, not investment advice and not a solicitation to buy or sell. All figures without guarantee.

Was this page helpful to you?

Income Statement

Cookie settings